Please join Trevi Therapeutics for its Investor and Analyst Day. During the program, Trevi’s leadership team will outline its clinical development plans, commercial learnings, and discuss the IP strategy. The event will also feature presentations from distinguished key opinion leaders (KOLs) in chronic cough in idiopathic pulmonary fibrosis and non-IPF interstitial lung disease, as well as refractory chronic cough.